BC Week In Review | May 5, 2014
Clinical News

Zolpidem-containing medicines regulatory update

EMA's Coordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh) endorsed a recommendation by the agency's Pharmacovigilance Risk Assessment Committee (PRAC) that the product information of zolpidem-containing medicines used for short-term treatment of insomnia further...
BC Week In Review | Apr 7, 2014
Company News

NovaDel neurology news

NovaDel said it will submit a recommendation to shareholders to dissolve the company and liquidate its assets. Pending shareholder approval and the sale of NovaDel's last remaining drug asset - ZolpiMist zolpidem tartrate - the company expects...
BC Week In Review | Mar 17, 2014
Clinical News

Zolpidem-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that the product information of zolpidem-containing medicines used for short-term treatment of insomnia further highlight the risks of impaired driving and mental alertness and strengthen warnings and precautions...
BC Week In Review | Aug 19, 2013
Company News

NovaDel, Suda deal

NovaDel completed the sale of "substantially all" of its assets - including its NovaMist sublingual delivery technology - to Suda for an upfront payment of $400,000 plus 50 million shares of Suda stock and an option to...
BC Week In Review | Jul 22, 2013
Clinical News

Zolpidem-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) began a review of zolpidem-containing medicines for short-term relief of insomnia following concerns that some patients may experience drowsiness and slower reactions the day after taking the drug. The...
BC Week In Review | Apr 15, 2013
Company News

NovaDel, Suda deal

NovaDel will sell its NovaMist sublingual delivery technology along with other assets to Suda for an upfront payment of $400,000 plus 50 million shares of Suda stock and an option to purchase 10 million shares...
BC Week In Review | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to...
BC Week In Review | Jan 14, 2013
Clinical News

Zolpidem-containing medicines regulatory update

FDA will require manufacturers of zolpidem-containing insomnia drugs to lower the recommended doses for women and suggest that prescribers consider lower doses for men. The requirement follows data from driving simulation and laboratory studies showing...
BC Week In Review | Jan 7, 2013
Company News

NovaDel, Suda deal

On Dec. 26, 2012, NovaDel said it granted Suda an option to acquire NovaMist sublingual delivery technology and other products. The companies declined to disclose financial terms. The option covers IP related to NovaMist, plus...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
Items per page:
1 - 10 of 138
BC Week In Review | May 5, 2014
Clinical News

Zolpidem-containing medicines regulatory update

EMA's Coordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh) endorsed a recommendation by the agency's Pharmacovigilance Risk Assessment Committee (PRAC) that the product information of zolpidem-containing medicines used for short-term treatment of insomnia further...
BC Week In Review | Apr 7, 2014
Company News

NovaDel neurology news

NovaDel said it will submit a recommendation to shareholders to dissolve the company and liquidate its assets. Pending shareholder approval and the sale of NovaDel's last remaining drug asset - ZolpiMist zolpidem tartrate - the company expects...
BC Week In Review | Mar 17, 2014
Clinical News

Zolpidem-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended that the product information of zolpidem-containing medicines used for short-term treatment of insomnia further highlight the risks of impaired driving and mental alertness and strengthen warnings and precautions...
BC Week In Review | Aug 19, 2013
Company News

NovaDel, Suda deal

NovaDel completed the sale of "substantially all" of its assets - including its NovaMist sublingual delivery technology - to Suda for an upfront payment of $400,000 plus 50 million shares of Suda stock and an option to...
BC Week In Review | Jul 22, 2013
Clinical News

Zolpidem-containing medicines regulatory update

EMA's Pharmacovigilance Risk Assessment Committee (PRAC) began a review of zolpidem-containing medicines for short-term relief of insomnia following concerns that some patients may experience drowsiness and slower reactions the day after taking the drug. The...
BC Week In Review | Apr 15, 2013
Company News

NovaDel, Suda deal

NovaDel will sell its NovaMist sublingual delivery technology along with other assets to Suda for an upfront payment of $400,000 plus 50 million shares of Suda stock and an option to purchase 10 million shares...
BC Week In Review | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to...
BC Week In Review | Jan 14, 2013
Clinical News

Zolpidem-containing medicines regulatory update

FDA will require manufacturers of zolpidem-containing insomnia drugs to lower the recommended doses for women and suggest that prescribers consider lower doses for men. The requirement follows data from driving simulation and laboratory studies showing...
BC Week In Review | Jan 7, 2013
Company News

NovaDel, Suda deal

On Dec. 26, 2012, NovaDel said it granted Suda an option to acquire NovaMist sublingual delivery technology and other products. The companies declined to disclose financial terms. The option covers IP related to NovaMist, plus...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
Items per page:
1 - 10 of 138